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Abstract: Acute parvovirus B19 (B19V) infection in immunocompromised patients may lead to severe
anemia. However, in adult transplant recipients, B19V reactivations without anemia and low-level
viremia are common. The impact of B19V in pediatric transplant patients, with high risk of primary
infection, is investigated here. In a six-month period, 159 blood samples of 54 pediatric liver transplant
recipients were tested for B19V DNA by quantitative real-time PCR. Viremia was correlated with
anemia and immunosuppression and compared with rates in adult transplant recipients. B19V DNA
was detected in 5/54 patients. Primary B19V infections were observed in four patients prior to and in
one patient after transplantation. Rates of viremia were significantly higher in pediatric recipients
than in adults. Prolonged virus shedding after primary infection prior to transplantation accounts for
most viremic cases. Anemia was significantly more frequent in samples from viremic patients, but
remained mild. In 15% of anemic samples, B19V DNA was detected. Therefore, in anemic pediatric
transplant recipients, diagnostics for B19V seem reasonable.
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1. Introduction
In immunocompetent individuals, acute parvovirus B19 (B19V) infection is a mild disease
associated with transient anemia, rash and arthritis. In contrast, in immunocompromised patients,
cases of persisting B19 viremia with severe life-threatening chronic anemia have been reported [1–3].
Those clinical courses occur in acute infections with high B19V DNA levels after solid organ
transplantation, whereas B19V reactivations are more likely in adult transplant recipients and lead to
low-level DNAemia, which is not associated with notable anemia [4,5]. Therefore, B19V does not seem
to be a frequently harmful pathogen in adult transplant recipients. However, children are at higher risk
of a primary B19V infection due to the low level of immunoglobulin G (IgG) seroprevalence [6]. It is
unclear if there is a higher rate of acute B19V infections and consequently severe anemia in pediatric
transplant recipients since larger studies are lacking.
The aims of this retrospective anonymous study were: (1) to assess the prevalence and quantity of
B19V DNA, to determine the respective B19V genotypes and the serostatus at liver transplantation
among pediatric patients, and (2) to correlate the occurrence of B19 viremia with hemoglobin levels
and reticulocyte counts as surrogate markers of pure red cell aplasia and to compare these findings
with previously published data on B19V prevalence in adult transplant recipients [4].
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2. Materials and Methods
For retrospective analysis, pediatric patients between 0 and 18 years who had undergone liver
transplantation in the pediatric university hospital of Regensburg between 2008 and 2012 were eligible
for the study. Remaining samples from routine blood analyses derived from a period of six months
after transplantation were tested for B19V DNA. Follow-up samples were selected at intervals of
30 days or as close as possible to these dates. In case of re-transplantation follow-up was extended or
extra cases were defined. All samples were analyzed for B19V DNA (genotypes 1–3) by quantitative
real-time PCR. Hemoglobin levels and reticulocyte counts of each analyzed sample were recorded.
For assessment of the patients’ serostatus, B19V IgG was tested in pre-transplantation samples or, if
not available, shortly after transplantation. Because of intravenous immunoglobulins (IVIG) routinely
transfused in a large number of patients for cytomegalo virus (CMV) prophylaxis, which contributes
to the serostatus for several months, B19V IgG negative patients were tested again at one month to
assess the postoperative serostatus. Clinical data on underlying disease, immunosuppression, IVIG
transfusions and symptoms characteristic of B19V infection were obtained from the patient records.
All data were pseudonymized. The study was approved by the Ethics Committee of the University
Hospital of Regensburg on 31 March 2011 (reference number 11-101-0036).
B19V DNA was amplified using an in-house real-time quantitative TaqMan PCR assay including
all three genotypes according to the previously published protocol [4]. Purified B19V plasmids were
included as positive controls and for calibration and B19V-seronegative samples as negative controls.
The detection limit of the assay, defined as the DNA concentration with at least 95% of positive samples
detectable, was 600 genome equivalents (geq)/mL (215 IU/mL) for each genotype. Reproducible
positive results below the detection limit (<600 geq/mL) were described as ‘weakly positive’.
B19V specific IgG, immunoglobulin M (IgM), and IgG avidity were analyzed by enzyme immune
assay (EIA) and immunoblot according to the manufacturer’s instructions (recomWell parvovirus B19
IgG and IgM assay, Mikrogen, Neuried, Germany).
Reference levels of the Department of Clinical Chemistry and Laboratory Medicine of the
University Hospital of Regensburg were used for definition of anemia (Table 1).
Table 1. Characteristics of parvovirus B19 (B19V) DNA positive patients.
Patient ID, Gender,
Age (Years), Donor
Day
Post-Tx
DNA
(geq/mL) gt IgG IgG-Quantity
1 Hb (g/dL) Reti (h)
PLTX_02, m, 13, D −13 9200 pos +++
34 <600 1 pos +++ 10.3 * nd
70 <600 10.5 * nd
98 <600 10.6 * nd
164 0 pos +++ 9.4 * nd
PLTX_03, f, 11, D −148 1700 pos +++
30 680 1 pos +++ 7.9 * nd
59 <600 pos +++ 10.4 * nd
90 0 10.3 * nd
128 0 10.3 * nd
158 0 9.3 * nd
168 0 10.9 nd
PLTX_08, m, 10, D 0 1300 pos +++
32 0 8.3 * 33
59 0 nd nd
92 <600 1 pos +++ 10.1 * nd
118 0 pos +++ nd nd
146 0 12.0 nd
172 0 11.9 nd
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Table 1. Cont.
Patient ID, Gender,
Age (Years), Donor
Day
Post-Tx
DNA
(geq/mL) gt IgG IgG-Quantity
1 Hb (g/dL) Reti (h)
PLTX_19, m, 3, D −67 0 neg −−
(Re-Tx: day 143, D) 29 0 10.7 21
57 0 9.7 20
86 0 8.7 * 21
126 0 7.9 * nd
146 <600 1 neg −− 9,7 24
174 0 i −/+ 10.1 nd
242 <600 neg −− 10.1 6 *
347 440,000 i −/+ 9.4 nd
PLTX_28, f, 10, D 1 5100 pos +++ 9.5 * 14
30 3200 1 pos +++ 10.1 * 23
58 3600 9.3 * 24
129 3000 pos ++ 8.9 * 3 *
pos—positive; neg—negative; i—indeterminate; nd—not detected; m—male; f—female; D—deceased donor;
Hb—hemoglobin levels; Reti—reticulocyte counts. * levels indicating anemia or reticulocytopenia (age dependent
standard hemoglobin levels [g/dL]: 0–1 day: 17.7–26.5; 2–7 days: 16.2–25.5; 8–30 days: 10.1–24; 31–59 days: 9.2–18;
60–365 days: 9–14.6; 366–730 days: 9.1-15; 2–9 years: 9.2–15.5; 10–11 years: 10.7–16.5; 12–13 years: 10.8–16.2;
14–17 years: 11–15.9; 18–20 years (f): 11.2–15.7, 18–20 years (m): 13.7–17.5). 1 semiquantitative presentation:
indeterminate: −/+; 24.1–49.9 U/mL: +; 50.0–199.9 U/mL: ++; >200 U/mL: +++. Re-Tx: second transplantation;
post-Tx: post transplantation; gt: genotype; IgG: immunoglobulin G.
3. Results
3.1. Patients
A total of 51 pediatric liver transplant recipients met the inclusion criteria. Due to re-transplantations,
a total of 54 cases were analyzed. The median age was two years, 56% were female, 44% male. Thirty-six
liver transplantations were performed in infants, 15 patients where six years or older. In patients in
infancy almost 2/3 suffered from biliary atresia, whereas patients aged six years or older mostly suffered
from cystic fibrosis and autoimmune hepatitis. A total of 159 samples were available for analysis.
3.2. B19V DNA Detection
Within the first six months post-transplantation (post-Tx), in 12 samples (7.6%) from five patients
(9.3%) B19V DNA was detected after transplantation, in all cases B19V genotype 1. In 7/12 samples,
the B19V DNA load was <600 geq/mL, >103 geq/mL B19V-DNA/genotype 1 were detectable in four
and >105 geq/mL in one sample. In 3/5 (60%) of these patients, initial B19V DNA detection post-Tx
was at month 1, in one patient at month 3. In these four patients B19V DNA was already found in
pre-transplantation (pre-Tx) specimens, as well. In one pre-Tx DNA-negative patient initial B19V DNA
detection was at month 5, three days after re-transplantation (month 0). Thus, in all cases viremia was
observed within the first three months after transplantation.
3.3. B19V IgG Serostatus
B19V IgG was detected in 31.5% (17/54 patients) pre-Tx. In patients younger than one year, 5/20
were seropositive (0–4 months old). The four patients with viremia pre-Tx were also B19V IgG positive.
That means that 4 (23.5%) of 17 children with an earlier infection were still viremic. As five patients
had probably maternal antibodies, this number is raised to 4/12 (33.3%). In month 1, 70.4% (38/54)
were seropositive due to IVIG.
3.4. Dependence of Viremia on Immunosuppressive Regimen
In all cases an induction therapy with basiliximab was implemented. Mostly, immunosuppressive
regimens were used combining prednisolone with cyclosporine (56%) or tacrolimus (20.8%). Changes
of medication from cyclosporine to other immunosuppressive drugs were performed in the further course
of the observation period. Thus, we compared the immunosuppressive regimens with B19V viremia in
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each sample. B19V viremia was more frequent in tacrolimus-based than in cyclosporine-based regimens
(p = 0.0003): B19V viremia was observed in 10/50 tacrolimus-based regimens (20%), whereas viral
genomes were found only in 2/106 cyclosporine-based regimens (1.9%).
Furthermore, the correlation of B19V viremia with high dose prednisolone therapy
(≥60 mg/m2/day) used for treatment of acute rejection (13 patients, one patient twice) or for initiation
of immunosuppression (two patients) was evaluated. In 3/15 samples, B19V viremia was detectable
simultaneously to high-dose prednisolone administration (20%), whereas B19V DNA could be found
only in 9/144 of the remaining samples (6.3%). This difference was significant in Fisher’s exact test
(p = 0.036).
3.5. Association of Viremia and Hemoglobin Levels
Anemia was found in 17/27 samples (63.0%) from patients with B19V viremia, in contrast only in
43/132 samples (32.6%) of all 49 B19V negative patients. Also, anemia was more frequent in all B19V DNA
positive (9/12, 75%) samples than in all B19V DNA negative samples (50/145, 34.5%). Both comparisons
were highly significant (p = 0.003 and 0.006). There were also higher rates of reticulocytopenia in
viremic patients (20.0% vs. 14.3%) and samples (33.3% vs. 13.4%), respectively. Due to low number of
samples with reticulocyte counts, the significance of these findings remains unclear.
3.6. Case Report of a Primary B19V Infection after Pediatric Liver Transplantation
Patient PLTX_19, a three-year old boy suffering from progressive familial intrahepatic cholestasis,
primary B19V infection occurred after liver transplantation. He underwent re-transplantation after
143 days due to acute refractory rejection. B19V IgG was lacking despite IVIG transfusion after first
transplantation. He received high doses of prednisolone (≥60 mg/m2/day) and a tacrolimus-based
maintenance therapy in temporal relation to re-transplantation.
Parvovirus B19 DNA (<600 geq/mL) was detected for the first time three days after re-transplantation.
Unfortunately, neither the donor organ nor donor blood was available for testing, so it remains
unknown if the organ was the source of infection. The patient developed an itching exanthema
with target lesions and slapped cheeks two days after transplantation, consistent with the clinical
manifestation of the fifth disease. The course of viremia and other markers are depicted in Figure 1.
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Figure 1. Course of patient PLTX_19. For more than three years after initial detection, B19V DNA
was detectable with a maximal value of 105 geq/mL at month 7 after re-trans lantati n. During this
period, the patient was B19V IgG negative or indeterminate and became transiently B19V IgM positive
two years after re-transplantation. Anemia was present only two months before initial detection of
B19V DNA with hemoglobin levels be we n 7.9 g/dL and 8.7 g/dL. Reticulocytopenia (6h) was
detected only once in month 4 after second transplantation with low viral load at the same time.
CSA—Cyclosporine A. M—Mycophenolat Mofetil. Sir—Sirolimus. IgM—immunoglobulin M.
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3.7. Comparison of Pediatric and Adult Transplant Recipients Regarding Clinical Impact of B19V DNA Detection
The number of B19V DNA positive samples was significantly higher in pediatric than in adult
liver transplant patients (10.3% vs. 2.7%, p < 0.001) [4]. Also, the prevalence of B19 viremia was higher
in pediatric than adult liver transplant recipients (9.3% vs. 5.5%, not significant.).
In pediatric liver transplant patients, the overall rate of anemia was significantly lower than
in adult liver transplant recipients (37.7% vs. 81.5%, p < 0.001). However, in pediatric patients,
15.3% (9/59) of anemic samples simultaneously showed B19Viremia, whereas in adult liver transplant
patients this constellation was observed only in 2.6% (7/269) (p < 0.001).
4. Discussion
In this first larger study on B19V in pediatric transplant patients, a B19V DNA prevalence of
9.3% was found, which is markedly higher than previously estimated on the basis of case reports [7].
There were higher B19V DNA loads in pediatric patients with most likely a recent primary infection
pre-Tx [8–10] than in adult patients with reactivation [4]. In all patients, the B19V genotype 1 was
found, the most widely-spread genotype [11].Prolonged viremia after primary infection prior to
transplantation had a wider impact on anemia than reactivations after transplantation [4]. The level of
anemia seems to correlate with B19V DNA loads, since there is no anemia found in adult patients with
low-level B19V DNAemia [4,5], mild anemia in our pediatric collective with moderate viremia, and
severe anemia in immunocompromised patients with high-level viremia [1,2,12–15]. The overall rate
of anemia in pediatric liver transplant recipients was distinctly lower than in adult transplant patients
(37.7% vs. 84.2%) [4]. Lower rates of anemia in pediatric liver transplant patients are known [16],
the reasons remain unclear. It is remarkable that as many as 15.3% of samples with anemic hemoglobin
levels were simultaneously B19V DNA positive, similar to 19.2% in anemic pediatric liver transplant
recipients in a smaller collective [17]. Thus, B19V viremia can be regarded a major risk factor for
anemia in pediatric liver transplant recipients, in contrast to adults.
As many as one-third of all children with a former infection were still viremic at the time point
of transplantation and thus at risk for anemia. IVIG was routinely transfused in CMV high-risk
patients and in under-six-month-olds, which contributes to transient immunity [18–20]. This raised
the seroprevalence from 31.5% pre- to 70.4% post-Tx which is similar to that of adult transplant
recipients [4] and led to a low incidence of primary infections after transplantation (1/54, 1.9%),
comparable to that in adult transplant recipients (0.7%) [4].
The rate of B19V viremia in patients treated with tacrolimus-based regimens was significantly
higher than in patients treated with cyclosporine-based regimens. Other case reports also show pure
red-cell aplasia due to B19V infection after application of tacrolimus—in one case the infection remitted
only after switching to cyclosporine [21–23] as the immunosuppressive effect is lower [24,25]. Also
BK virus infections occur more frequently in patients with tacrolimus-based immunosuppression [26].
High doses of prednisone also led to a significantly higher rate of B19V infections, consistent with a
straight increase of CMV infection risk with cumulative methylprednisolone-dose [27].
There was one unusual case of a primary B19V infection post-Tx with an unknown source of
infection. Surprisingly, he presented with atypically low DNA-loads (<600–440,000 geq/mL), negative
antibodies, and did not have anemia at all, but showed an exanthema consistent with fifth disease two
days after transplantation. This manifestation is the result of immune complex formation [28], but in
this case, viral load was much too low to build enough immune complexes, specific IgG and IgM were
not detectable. As well, it remains unclear why high viral loads and prolonged pure red-cell aplasia
did not occur, as described before in several case reports [2,29,30]. This case and another one in a heart
transplanted adult [4] obviously show that not every primary infection necessarily leads to a severe
course of infection.
In this study, parvovirus B19V viremia most often occurred as a prolonged shedding of virus
after a primary infection prior to transplantation. It caused mild anemia. A primary infection post-Tx
surprisingly did not result in a severe course. However, as 15% of anemic samples were B19Viremic,
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we recommend performing diagnostics for B19V DNA in anemic pediatric transplant recipients though
routine screening after transplantation does not seem to be necessary.
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